Roivant Sciences Director Meghan Fitzgerald Exercises Options and Sells Shares Under 10b5-1 Plan

Executive Summary

On September 8, 2026, Meghan Fitzgerald, a member of the Board of Directors of Roivant Sciences Ltd. ($ROIV), executed an option exercise and corresponding sale of 20,000 Common Shares. The shares were sold at a weighted average price of $39.90 per share, yielding total gross proceeds of $798,000.

Transaction Details

1. Derivative Exercise:

   • Instrument: Stock Option (Right to Buy)
   • Shares Exercised: 20,000
   • Exercise Price: $8.80 per share
   • Remaining Derivative Holdings: 18,578 options

2. Open Market Sale:

   • Shares Sold: 20,000 Common Shares
   • Weighted Average Price: $39.90 (Price range: $39.90 to $40.00)
   • Total Consideration: $798,000
   • Remaining Direct Ownership: 42,963 Common Shares

Context and Analysis

• Rule 10b5-1 Trading Plan: The transaction was executed pursuant to a pre-established Rule 10b5-1 trading plan adopted on March 30, 2026.
• Significance Level: Low. The sale represents standard option monetisation executed automatically under a scheduled trading plan, resulting in zero net change to direct equity ownership aside from the option conversion.